Acute myeloid leukaemia

@article{Khwaja2016AcuteML,
  title={Acute myeloid leukaemia},
  author={Asim Ijaz Khwaja and Magnus Bjorkholm and Rosemary E. Gale and Ross L. Levine and Craig T. Jordan and Gerhard Ehninger and Clara Derber Bloomfield and Elihu H Estey and Alan K Burnett and Jan J Cornelissen and David A. Scheinberg and Didier Bouscary and David C. Linch},
  journal={Nature Reviews Disease Primers},
  year={2016},
  volume={2}
}
Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of myeloid cells results in a high level of immature malignant cells and fewer differentiated red blood cells, platelets and white blood cells. The disease occurs at all ages, but predominantly occurs in older people (>60 years of age). AML typically presents with a rapid onset of symptoms that are attributable to bone… Expand
Patient with Chronic Myeloid Leukemia: A Case Study
TLDR
The case of 58-year-old Asian lady experiencing generalized body weakness, pallor, left upper abdominal pain and sudden weight loss of 5 kg within three weeks and a high blood pressure is reported, indicating a myeloproliferative disorder. Expand
Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
  • R. Majeti
  • Biology, Medicine
  • Best practice & research. Clinical haematology
  • 2014
TLDR
Pre-leukemic HSC have been found to persist in clinical remission and may ultimately give rise to relapsed disease through the acquisition of novel mutations, which may constitute a key cellular reservoir that must be eradicated for long-term cures. Expand
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
TLDR
Overall, this Review links the cellular and molecular mechanisms regulating HSC behaviour with the functional dysregulation of these mechanisms in myeloid leukaemia and discusses opportunities for targeting LSC-specific mechanisms for the prevention or cure of malignant diseases. Expand
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
TLDR
The identification of patterns of mutation acquisition in human AML supports a model in which mutations in “landscaping” genes, involved in global chromatin changes such as DNA methylation, histone modification, and chromatin looping, occur early in the evolution of AML, whereas mutations in "proliferative" genes occur late. Expand
Acute Myeloid Leukemia—Genetic Alterations and Their Clinical Prognosis
TLDR
This review is focused on describing the most important molecular markers with implications for clinical practice: cytogenetic markers, which are used to stratify patients in three risk categories: favorable, intermediate and unfavorable. Expand
Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia
TLDR
Data suggest that decreasing numbers of hematopoietic stem cells indicate leukemic stem cell persistence and the emergence ofLeukemic relapse, and developed new mathematical models suggest that the mechanism leading to decreases in he matopoetic stem cell frequencies before leukedmic relapse must be based on expansion of leukeMic stem cells with high niche affinity and the ability to dislodge hematoietIC stem cells. Expand
Microarray-based genomic analysis identifies germline and somatic copy number variants and loss of heterozygosity in acute myeloid leukaemia
TLDR
A combined platform of CGH+SNP provides invaluable insights into the elucidation of large spectrum of genomic aberrations in AML which may have prognostic implications. Expand
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome
TLDR
Results show a link between the cycling speed of AML cells and the response to chemotherapy, and help to identify a group with a very poor prognosis. Expand
Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms
TLDR
It is concluded that even though the effects of single cytokines derived from bone marrow MSCs on human AML cells differ among patients, the final cytokine-mediated effects of the M SCs during coculture is growth enhancement and inhibition of apoptosis. Expand
HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML
  • Zheng Li, Fangce Wang, +5 authors A. Liang
  • Medicine
  • Journal of experimental & clinical cancer research : CR
  • 2021
TLDR
HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML and may be an ideal therapeutic target for eradicating LSCs without influencing normal haematopoiesis. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 775 REFERENCES
Advances in Understanding the Biology and Genetics of Acute Myelocytic Leukemia
  • S. B. Mckenzie
  • Biology
  • American Society for Clinical Laboratory Science
  • 2005
TLDR
The most recent understanding and research of the cellular origin of AML and associated common genetic mutations that fuel the neoplastic process are discussed and how these advances have impacted the classification, selection of therapy, and definition of complete remission in AML are discussed. Expand
Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm
TLDR
Recent advances in the understanding of the molecular events that contribute to the development of leukemic transformation will need to be utilized in order to produce rational therapeutic approaches for this largely fatal disease. Expand
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
TLDR
Analysis of serial samples from individual patients revealed that the presence of a mutation in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 was >95% specific for the diagnosis of s-AML and highlights a subset of patients with worse clinical outcomes, including a lower complete remission rate, more frequent reinduction, and decreased event-free survival. Expand
The epidemiology of acute promyelocytic leukaemia.
  • D. Douer
  • Medicine
  • Best practice & research. Clinical haematology
  • 2003
TLDR
This chapter shows that epidemiological characteristics of APL are different from those of non-APL AML using data from the Los Angeles tumour registry and other sources and might lead to better understanding of specific aetiological factors in APL patients. Expand
How I treat hyperleukocytosis in acute myeloid leukemia.
TLDR
Whereas initial high blood counts and high lactate dehydrogenase as an indicator for high proliferation are part of prognostic scores guiding risk-adapted consolidation strategies, HL at initial diagnosis must be considered a hematologic emergency and requires rapid action of the admitting physician in order to prevent early death. Expand
Hematopoietic stem cells are intrinsically protected against MLL-ENL-mediated transformation.
TLDR
It is shown that AML can originate from multiple hematopoietic progenitor subsets with granulocytic and monocytic potential, and that the normal developmental position of leukemia-initiating cells influences leukemic development, but disease failed to arise from HSCs. Expand
Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes.
TLDR
Cytogenetic and molecular analyses may allow clinicians to more appropriately direct types of treatment and sometimes predict clinical outcome and thus also serve as prognostic parameters, which may affect the therapeutic decision. Expand
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
TLDR
Clonal heterogeneity was associated with decreased response rates and inferior event-free, relapse-free and overall survival, and was confirmed as an independent predictor of poor prognosis in multivariable analysis and subgroup analysis showed that clonal heterogeneity adds prognostic information particularly in the unfavorable karyotype group. Expand
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
TLDR
It is demonstrated that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) — termed the SCID leukemia-initiating cell, or SL-IC — possesses the differentiate and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. Expand
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice.
TLDR
It is confirmed that human leukemic stem cells, functionally defined by us as SCID leukemia-initiating cells (SL-ICs), are rare in acute myelogenous leukemia (AML) and suggested a plasticity of the cancer stem cell phenotype that has not been previously described. Expand
...
1
2
3
4
5
...